Project description: 

This Phase 2 study was designed to test, in Thai adults, safety and immunogenicity of RTS,S/AS01 administered in conjunction with anti-malarial drugs. If results are promising, it will form the basis for assessing the impact of RTS,S/AS01 vaccination in targeted malaria elimination programs in the Greater Mekong Subregion.


Related resources:

Tun KM, Imwong M, Lwin KM, Win AA, Hlaing MM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. The Lancet Infectious Diseases. 2015 Feb 19; 15(4): 415-21.

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, et al. Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a Phase 2a controlled human malaria infection and immunogenicity study. The Journal of Infectious Diseases. 2016;214(5):762–771. Identifier: NCT02992119

View detailed study record on